UNSPSC 51162409: Dextromethorphan/guaifenesin/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE513. This VA Drug Class (RE513) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE/EXPECTORANT.

UNSPSC 51162409 Dextromethorphan/guaifenesin/phenylpropanolamine is a Commodity code representing pharmaceutical products and over-the-counter medications that state and local governments procure for community health, public safety, and emergency response initiatives. Recent solicitations show state and local bodies buying naloxone and drug deactivation systems for harm reduction and opioid emergency response, as well as generic multi-source pharmaceuticals and OTC products for distribution across government health facilities. Issuing bodies include county health departments, state purchasing offices administering cooperative purchasing agreements, and multistate cooperative groups. The Minnesota Department of Administration's Office of State Procurement administers MMCAP (Minnesota Multistate Cooperative Purchasing Alliance) to serve participating state and local government facilities across multiple states including Oregon, reflecting the cooperative purchasing model common in pharmaceutical procurement at the state and local level.

Recent activity spans Florida and Minnesota-led multistate purchasing. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, requiring vendors to supply through authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with awarded products effective July 1, 2026. Both solicitations require compliance with manufacturing standards, insurance requirements, and federal regulations; vendors must hold current Good Manufacturing Practices certifications and demonstrate pricing flexibility across multiple cost structures.